These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11359403)

  • 41. Genetic aspects of deficiency of the ninth component of complement in man.
    Lint TF; Zeitz HJ; Gewurz H
    Immunobiology; 1980; 158(1-2):107-11. PubMed ID: 7193646
    [No Abstract]   [Full Text] [Related]  

  • 42. Erythroderma and extensive poikiloderma - a rare initial presentation of dermatomyositis: a case report.
    Herath HMMTB; Keragala BSDP; Pahalagamage SP; Janappriya GHCC; Kulatunga A; Gunasekera CN
    J Med Case Rep; 2018 Mar; 12(1):83. PubMed ID: 29571300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9.
    Falcão DA; Reis ES; Paixão-Cavalcante D; Amano MT; Delcolli MI; Florido MP; Albuquerque JA; Moraes-Vasconcelos D; Duarte AJ; Grumach AS; Isaac L
    Scand J Immunol; 2008 Oct; 68(4):445-55. PubMed ID: 18782275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic neutropenia associated with C2 and C9 deficiency.
    Kaneko Y; Tsukamoto A; Uwatoko S; Kurokawa K; Maeda H; Kuwata S; Tokunaga K; Juji T
    Int Arch Allergy Immunol; 1993; 102(3):304-6. PubMed ID: 8219785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Founder effect of the C9 R95X mutation in Orientals.
    Khajoee V; Ihara K; Kira R; Takemoto M; Torisu H; Sakai Y; Guanjun J; Hee PM; Tokunaga K; Hara T
    Hum Genet; 2003 Mar; 112(3):244-8. PubMed ID: 12596049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis.
    Nagata M; Hara T; Aoki T; Mizuno Y; Akeda H; Inaba S; Tsumoto K; Ueda K
    J Pediatr; 1989 Feb; 114(2):260-4. PubMed ID: 2915285
    [No Abstract]   [Full Text] [Related]  

  • 47. Genomic characterization and expression analysis of complement component 9 in rock bream (Oplegnathus fasciatus).
    Wickramaarachchi WD; Wan Q; Lee Y; Lim BS; De Zoysa M; Oh MJ; Jung SJ; Kim HC; Whang I; Lee J
    Fish Shellfish Immunol; 2012 Oct; 33(4):707-17. PubMed ID: 22796422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Component deficiencies. 9. The ninth component.
    Lint TF; Gewurz H
    Prog Allergy; 1986; 39():307-10. PubMed ID: 3562471
    [No Abstract]   [Full Text] [Related]  

  • 49. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
    Basta M; Dalakas MC
    J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pedigree of deficiency of the ninth component of complement (C9).
    Kusaba T; Kisu T; Inaba S; Sakai K; Okochi K; Yanase T
    Jinrui Idengaku Zasshi; 1983 Dec; 28(4):239-48. PubMed ID: 6379229
    [No Abstract]   [Full Text] [Related]  

  • 51. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL; Monahan JB; Brickner A; Sodetz JM
    Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization.
    Tschopp J; Podack ER; Müller-Eberhard HJ
    J Immunol; 1985 Jan; 134(1):495-9. PubMed ID: 3964819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.
    Joiner KA; Schmetz MA; Sanders ME; Murray TG; Hammer CH; Dourmashkin R; Frank MM
    Proc Natl Acad Sci U S A; 1985 Jul; 82(14):4808-12. PubMed ID: 3895225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Juvenile dermatomyositis induced by toxoplasmosis.
    Schröter HM; Sarnat HB; Matheson DS; Seland TP
    J Child Neurol; 1987 Apr; 2(2):101-4. PubMed ID: 3598137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
    Sims PJ
    Biochim Biophys Acta; 1983 Aug; 732(3):541-52. PubMed ID: 6871214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.
    Fu X; Ju J; Lin Z; Xiao W; Li X; Zhuang B; Zhang T; Ma X; Li X; Ma C; Su W; Wang Y; Qin X; Liang S
    Sci Rep; 2016 Jul; 6():30239. PubMed ID: 27444648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacterial killing by complement. C9-mediated killing in the absence of C5b-8.
    Dankert JR; Esser AF
    Biochem J; 1987 Jun; 244(2):393-9. PubMed ID: 3311029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The metabolism of C9 in normal subjects and in patients with autoimmune disease.
    Greenstein JD; Peake PW; Charlesworth JA
    Clin Exp Immunol; 1996 Apr; 104(1):160-6. PubMed ID: 8603521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.